Overview

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Status:
Not yet recruiting
Trial end date:
2029-09-03
Target enrollment:
Participant gender:
Summary
This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals